ArticleEuropean journal of medical research2025
Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is a prevalent and aggressive form of kidney cancer. Recently, the identification of suitable subtypes in ccRCC for the prediction of prognosis and immune infiltration remains limited. Kinesin superfamily proteins (KIFs), a group of molecular motor proteins, have been found to play crucial roles in tumor progression and patient prognosis in various cancers. However, the subtypes in ccRCC based on KIFs remain poorly understood.
methodsIn this study, transcriptional profiles of ccRCC were analyzed using data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Differential expression of KIFs was identified using R software. Subsequently, ccRCC patients were stratified into two distinct subgroups based on non-negative matrix factorization (NMF) analysis. Comparative analyses were performed to evaluate prognosis, mutations, and immune cell infiltration between these subtypes. Furthermore, signature genes associated with the identified subtypes were determined, followed by an investigation into their relationship with clinical characteristics and response to immune checkpoint inhibitors. Validation studies involving immunohistochemical staining, malignant phenotype assays, and immunofluorescence were conducted to assess the expression and function of these signature genes.
resultsFive KIFs genes, namely, KIF21B, KIF18B, KIF20A, KIF4A, and KIF13B, were identified as classifiers for categorizing ccRCC patients into two distinct subtypes known as KPCS1 and KPCS2. The aggressive subtype, KPCS2, was found to be associated with poorer survival outcomes. Furthermore, higher immune infiltration and copy number variations were observed in the KPCS2 subtype. Four signature genes (SLCA15, WDR72, PSAT1, and HJURP) displayed significant correlations with clinical characteristics and were determined to be linked to the ccRCC subtypes. The expression patterns and functional roles of these signature genes were subsequently validated in both ccRCC cells and tissues.
conclusionKIFs-associated subtypes provide valuable insights into the molecular characteristics and prognostic implications of ccRCC, thereby suggesting potential therapeutic targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.